drugset / Trial / NCT03016091
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
NaSingle-groupOpen-labelTreatment
Summary
A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Timeline
- Start
- 2018-01-01
- Primary completion
- 2022-07-01
- Completion
- 2022-12-01
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrural, dismal results”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |